News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Solvay Chemicals Inc. Sells Caprolactones Unit for 200 Million Euros
October 15, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
BRUSSELS, Oct 15 (Reuters) - Belgian drugs, chemicals and plastics maker Solvay (SOLB.BR: Quote, Profile, Research) said on Monday it had sold its Caprolactones business for 200 million euros ($284.3 million) to Sweden's Perstorp Group.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Europe
MORE ON THIS TOPIC
Earnings
‘We’re Not Done’: Roche Plans To Sustain Dealmaking Pace After 89bio
October 23, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Alkermes’ up to $2.1B Purchase of Avadel Sets Groundwork for ‘Strategic Evolution’
October 23, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Ipsen Puts Up $1.6B To Absorb ImCheck for Mid-Stage Leukemia Antibody
October 22, 2025
·
1 min read
·
Dan Samorodnitsky
Antibody-drug conjugate (ADC)
Takeda Bets up to $11.4B for Up To Three Innovent Cancer Assets
October 22, 2025
·
2 min read
·
Tristan Manalac
